Known drug space as a metric in exploring the boundaries of drug-like chemical space.

[1]  Jóhannes Reynisson,et al.  Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. , 2009, European journal of medicinal chemistry.

[2]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[3]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[4]  Gabriela L. Borosky,et al.  Carcinogenic carbocyclic and heterocyclic aromatic amines: a DFT study concerning their mutagenic potency. , 2008, Journal of molecular graphics & modelling.

[5]  V. Arlt,et al.  Mutagenic potential of nitrenium ions of nitrobenzanthrones: Correlation between theory and experiment , 2008, Environmental and molecular mutagenesis.

[6]  Jóhannes Reynisson,et al.  Benchmarking the reliability of QikProp. Correlation between experimental and predicted values , 2008 .

[7]  H. Glatt,et al.  Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  M. Novak,et al.  Synthesis and decomposition of an ester derivative of the procarcinogen and promutagen, PhIP, 2-amino-1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridine: unusual nitrenium ion chemistry. , 2007, The Journal of organic chemistry.

[9]  Gabriela L. Borosky,et al.  Ultimate carcinogenic metabolites from aromatic and heterocyclic aromatic amines: a computational study in relation to their mutagenic potency. , 2007, Chemical research in toxicology.

[10]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[11]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[12]  C. Laggner,et al.  Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.

[13]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[14]  Andrew M Davis,et al.  Components of successful lead generation. , 2005, Current topics in medicinal chemistry.

[15]  B. Sopko,et al.  Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.

[16]  Brian K. Shoichet,et al.  Virtual Screening in Drug Discovery , 2005 .

[17]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[18]  Paolo Vineis,et al.  Outdoor air pollution and lung cancer: Recent epidemiologic evidence , 2004, International journal of cancer.

[19]  Michael S Lajiness,et al.  Assessment of the consistency of medicinal chemists in reviewing sets of compounds. , 2004, Journal of medicinal chemistry.

[20]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[21]  D. M. Vera,et al.  Species with negative electron affinity and standard DFT methods , 2004 .

[22]  J. Reynisson,et al.  Hydrogen bonding between histidine and lignin model compounds or redox mediators as calculated with the DFT method. Effects on the ease of oxidation. , 2004, Organic & biomolecular chemistry.

[23]  Fredrik Nyberg,et al.  Contribution of environmental factors to cancer risk. , 2003, British medical bulletin.

[24]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[25]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[26]  S. Rajagopal,et al.  Correlations of nitrenium ion selectivities with quantitative mutagenicity and carcinogenicity of the corresponding amines. , 2002, Chemical research in toxicology.

[27]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[28]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[29]  I. Lambert,et al.  Salmonella typhimurium mutagenicity tester strains that overexpress oxygen-insensitive nitroreductases nfsA and nfsB. , 2002, Mutation research.

[30]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[31]  J. Ho,et al.  N-Hydroxyarylamine O-Acetyltransferase-Deficient Escherichia coli Strains Are Resistant to the Mutagenicity of Nitro Compounds , 2002, Biological chemistry.

[32]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[33]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[34]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[35]  M. Noble,et al.  Structure of arylamine N-acetyltransferase reveals a catalytic triad , 2000, Nature Structural Biology.

[36]  Wolfram Koch,et al.  A Chemist's Guide to Density Functional Theory , 2000 .

[37]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[38]  Krishnan Raghavachari,et al.  Assessment of Gaussian-2 and density functional theories for the computation of ionization potentials and electron affinities , 1998 .

[39]  Gregory S. Tschumper,et al.  PREDICTING ELECTRON AFFINITIES WITH DENSITY FUNCTIONAL THEORY: SOME POSITIVE RESULTS FOR NEGATIVE IONS , 1997 .

[40]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[41]  J. Sangster,et al.  Octanol‐Water Partition Coefficients of Simple Organic Compounds , 1989 .

[42]  J. Stewart.  Optimization of parameters for semiempirical methods II. Applications , 1989 .

[43]  R. Harvey.  Polycyclic hydrocarbons and carcinogenesis , 1985 .

[44]  D. Golden,et al.  Hydrocarbon Bond Dissociation Energies , 1983 .

[45]  G. Kauffman.  The discovery of penicillin: Twentieth century wonder drug , 1979 .

[46]  J. Miller,et al.  Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. , 1977, Cancer research.

[47]  J. Kerr.  Bond Dissociation Energies by Kinetic Methods , 1966 .

[48]  Tudor I. Oprea,et al.  Current trends in lead discovery: Are we looking for the appropriate properties? , 2004, Molecular Diversity.

[49]  D. Kyriacou.  Modern Electroorganic Chemistry , 1994 .

[50]  M. Lee,et al.  Microbial mutagenicity of isomeric two-, three-, and four-ring amino polycyclic aromatic hydrocarbons. , 1984, Environmental mutagenesis.

[51]  M. Baizer,et al.  Organic electrochemistry;: An introduction and a guide , 1973 .